Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors

Transplantation

Volumn 63, Issue 5, 1997, Pages 749-758

  Kopp, Christoph W ^a   Siegel, Jonathan B ^a   Hancock, Wayne W ^a   Anrather, Josef ^a   Winkler, Hans ^a   Geczy, Carolyn L ^b   Kaczmarek, Elzbieta ^a   Bach, Fritz H ^a   Robson, Simon C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; INTERCELLULAR ADHESION MOLECULE 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CLOTTING; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; LEUKOCYTE CULTURE; PRIORITY JOURNAL; PROTEIN INTERACTION; SPECIES DIFFERENTIATION; SWINE; THROMBOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTICOAGULANTS; AORTA; BLOTTING, NORTHERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIUM, VASCULAR; FACTOR VIIA; FACTOR XA; FLOW CYTOMETRY; HEART TRANSPLANTATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; MONOCYTES; SEQUENCE ALIGNMENT; SWINE; THROMBOPLASTIN;

EID: 0030897023     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199703150-00023     Document Type: Article

References (46)

1. Bach FH, Robson SC, Winkler H, et al. Barriers to xenotransplantation [Review]. Nature Med 1995; 1: 869.
2. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037.
3. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
4. Bach FH, Robson SC, Ferran C, et al. Endothelial cell activation and thromboregulation during xenograft rejection [Review]. Immunol Rev 1994; 141: 5.
5. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress [Review]. Immunol Today 1990; 11: 450.
6. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease [Review]. Blood Coagul Fibrinolysis 1995; 6 (suppl 1): S26.
7. Osterud B. Cellular interactions in tissue factor expression by blood monocytes [Review]. Blood Coagul Fibrinolysis 1995; 6 (suppl 1): S20.
8. Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 1992; 80: 966.
9. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1.
10. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces: comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121.
11. Marcum JA, Rosenberg RD. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium [Review]. Semin Thromb Hemost 1987; 13: 464.
12. Kojima T, Katsumi A, Yamazaki T, et al. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor and tissue factor pathway inhibitor. J Biol Chem 1996; 271: 5914.
13. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism [Review]. Am J Med 1989; 87: 2S.
14. Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI): evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 1998; 268: 8704.
15. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor [Review]. Biochemistry 1990; 29: 7539.
16. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001.
17. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518.
18. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004.
19. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661.
20. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773.
21. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353.
22. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869.
23. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219.
24. Grabowski EF, Zuckerman DB, Nemerson Y. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 1993; 81: 3265.
25. Warren JB. The endothelium: an introduction to current research. In: Warren JB, ed. New York: Wiley-Liss, 1990: 263.
26. Kamei S, Kamikubo Y, Hamuro T, et al. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem 1994; 115: 708.
27. Enjyoji K, Emi M, Mukai T, Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem 1992; 111: 681.
28. Wesselschmidt RL, Girard TJ, Broze GJ. cDNA sequence of rabbit lipoprotein-associated coagulation inhibitor. Nucleic Acids Res 1990; 18: 6440.
29. Hancock WW, Gee D, de Moerloose P, Rickles FR, Ewan VA, Atkins AC. Immunohistochemical analysis of serial biopsies taken during human renal allograft rejection: changing profile of infiltrating cells and involvement of the coagulation system. Transplantation 1985; 39: 430.
30. Godal HC. A comparison of two heparin-neutralizing agents: protamine and polybrene. Scand J Clin Lab Invest 1960; 12: 446.
31. Huang ZF, Wun TC, Broze GJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950.
32. Gustafson ME, Junger KD, Wun TC, et al. Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli. Protein Expr Purif 1994; 5: 233.
33. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995; 181: 21.
34. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol 1995; 154: 4768.
35. Takahashi M, Ikeda U, Masuyama J, et al. Involvement of adhesion molecules in human monocyte adhesion to and transmigration through endothelial cells in vitro. Atherosclerosis 1994; 108: 73.
36. Spokas EG, Wun TC. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods 1992; 27: 225.
37. Warn CB, Almus FE, Rapaport SI. Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb Haemost 1989; 61: 101.
38. Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394.
39. Wun TC, Kretzmer KK, Palmier MO, et al. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. Thromb Haemost 1992; 68: 54.
40. Esmon CT. Molecular events that control the protein C anticoagulant pathway [Review]. Thromb Haemost 1993; 70: 29.
41. Gimbrone MA Jr. Vascular endothelium: nature's blood-compatible container. Ann NY Acad Sci 1987; 516: 5.
42. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73: 159.
43. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties: modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor [published erratum appears in J Biol Chem 1990 Aug 25;265(24):14696]. J Biol Chem 1989; 264: 20705.
44. Platt JL, Vercellotti GM, Lindman BJ, Oegema TJ, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
45. Candinas D, Koyamada N, Miyatake T, et al. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 1996; 76: 807.
46. Dalmasso AP, Platt JL, Bach FH. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 1991; 1: 31.